SciVision Biotech Inc (1786) - Net Assets
Based on the latest financial reports, SciVision Biotech Inc (1786) has net assets worth NT$1.86 Billion TWD (≈ $58.58 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$2.75 Billion ≈ $86.69 Million USD) and total liabilities (NT$892.04 Million ≈ $28.10 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SciVision Biotech Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.86 Billion |
| % of Total Assets | 67.58% |
| Annual Growth Rate | 21.83% |
| 5-Year Change | 36.58% |
| 10-Year Change | 121.45% |
| Growth Volatility | 62.33 |
SciVision Biotech Inc - Net Assets Trend (2009–2025)
This chart illustrates how SciVision Biotech Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is SciVision Biotech Inc worth.
Annual Net Assets for SciVision Biotech Inc (2009–2025)
The table below shows the annual net assets of SciVision Biotech Inc from 2009 to 2025. Also explore 1786 net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.98 Billion ≈ $62.39 Million |
+4.38% |
| 2024-12-31 | NT$1.90 Billion ≈ $59.77 Million |
+16.63% |
| 2023-12-31 | NT$1.63 Billion ≈ $51.24 Million |
+7.65% |
| 2022-12-31 | NT$1.51 Billion ≈ $47.60 Million |
+4.21% |
| 2021-12-31 | NT$1.45 Billion ≈ $45.68 Million |
+3.25% |
| 2020-12-31 | NT$1.40 Billion ≈ $44.24 Million |
+3.19% |
| 2019-12-31 | NT$1.36 Billion ≈ $42.87 Million |
+26.22% |
| 2018-12-31 | NT$1.08 Billion ≈ $33.97 Million |
+17.89% |
| 2017-12-31 | NT$914.45 Million ≈ $28.81 Million |
+2.26% |
| 2016-12-31 | NT$894.21 Million ≈ $28.17 Million |
-5.73% |
| 2015-12-31 | NT$948.60 Million ≈ $29.89 Million |
-7.28% |
| 2014-12-31 | NT$1.02 Billion ≈ $32.23 Million |
-5.60% |
| 2013-12-31 | NT$1.08 Billion ≈ $34.15 Million |
+154.43% |
| 2012-12-31 | NT$425.98 Million ≈ $13.42 Million |
+17.12% |
| 2011-12-31 | NT$363.70 Million ≈ $11.46 Million |
+225.51% |
| 2010-12-31 | NT$111.73 Million ≈ $3.52 Million |
+32.87% |
| 2009-12-31 | NT$84.09 Million ≈ $2.65 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SciVision Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 38962200000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$158.71 Million | 8.01% |
| Common Stock | NT$748.28 Million | 37.79% |
| Other Comprehensive Income | NT$148.50 Million | 7.50% |
| Other Components | NT$924.75 Million | 46.70% |
| Total Equity | NT$1.98 Billion | 100.00% |
SciVision Biotech Inc Competitors by Market Cap
The table below lists competitors of SciVision Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JW Shinyak Corporation
KQ:067290
|
$100.24 Million |
|
Balyo SA
PA:BALYO
|
$100.24 Million |
|
Thai Plaspac Public Company Limited
BK:TPAC
|
$100.26 Million |
|
Acconeer AB
ST:ACCON
|
$100.30 Million |
|
Leadtrend Technology Corp
TW:3588
|
$100.20 Million |
|
Bombay Super Hybrid Seeds Limited
NSE:BSHSL
|
$100.15 Million |
|
Definitive Healthcare Corp
NASDAQ:DH
|
$100.11 Million |
|
Supercomnet Technologies Bhd
KLSE:0001
|
$100.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SciVision Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,897,051,000 to 1,980,234,000, a change of 83,183,000 (4.4%).
- Net income of 162,338,000 contributed positively to equity growth.
- Dividend payments of 233,871,000 reduced retained earnings.
- Other comprehensive income increased equity by 148,694,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$162.34 Million | +8.2% |
| Dividends Paid | NT$233.87 Million | -11.81% |
| Other Comprehensive Income | NT$148.69 Million | +7.51% |
| Other Changes | NT$6.02 Million | +0.3% |
| Total Change | NT$- | 4.38% |
Book Value vs Market Value Analysis
This analysis compares SciVision Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.60x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 21.61x to 1.60x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$2.02 | NT$43.75 | x |
| 2010-12-31 | NT$2.55 | NT$43.75 | x |
| 2011-12-31 | NT$7.12 | NT$43.75 | x |
| 2012-12-31 | NT$8.05 | NT$43.75 | x |
| 2013-12-31 | NT$20.10 | NT$43.75 | x |
| 2014-12-31 | NT$16.45 | NT$43.75 | x |
| 2015-12-31 | NT$15.54 | NT$43.75 | x |
| 2016-12-31 | NT$14.91 | NT$43.75 | x |
| 2017-12-31 | NT$15.23 | NT$43.75 | x |
| 2018-12-31 | NT$18.08 | NT$43.75 | x |
| 2019-12-31 | NT$19.34 | NT$43.75 | x |
| 2020-12-31 | NT$19.80 | NT$43.75 | x |
| 2021-12-31 | NT$20.43 | NT$43.75 | x |
| 2022-12-31 | NT$20.24 | NT$43.75 | x |
| 2023-12-31 | NT$21.28 | NT$43.75 | x |
| 2024-12-31 | NT$25.47 | NT$43.75 | x |
| 2025-12-31 | NT$27.32 | NT$43.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SciVision Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.20%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.31%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.35x
- Recent ROE (8.20%) is above the historical average (2.40%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -62.47% | -335.00% | 0.08x | 2.24x | NT$-60.94 Million |
| 2010 | -6.14% | -10.37% | 0.30x | 2.00x | NT$-18.04 Million |
| 2011 | 14.07% | 35.71% | 0.35x | 1.11x | NT$14.79 Million |
| 2012 | 14.66% | 31.11% | 0.42x | 1.13x | NT$19.83 Million |
| 2013 | 3.72% | 20.12% | 0.18x | 1.04x | NT$-68.03 Million |
| 2014 | -2.16% | -13.99% | 0.14x | 1.07x | NT$-124.45 Million |
| 2015 | 5.78% | 20.71% | 0.25x | 1.13x | NT$-40.02 Million |
| 2016 | -2.94% | -11.50% | 0.17x | 1.52x | NT$-115.68 Million |
| 2017 | 1.87% | 6.63% | 0.17x | 1.71x | NT$-74.31 Million |
| 2018 | 8.06% | 26.36% | 0.19x | 1.57x | NT$-20.94 Million |
| 2019 | 8.87% | 27.57% | 0.24x | 1.37x | NT$-15.37 Million |
| 2020 | 9.12% | 27.42% | 0.25x | 1.35x | NT$-12.41 Million |
| 2021 | 7.02% | 20.12% | 0.22x | 1.56x | NT$-43.27 Million |
| 2022 | 9.38% | 25.43% | 0.27x | 1.39x | NT$-9.38 Million |
| 2023 | 10.94% | 24.95% | 0.33x | 1.33x | NT$15.25 Million |
| 2024 | 12.77% | 27.43% | 0.38x | 1.24x | NT$52.55 Million |
| 2025 | 8.20% | 18.31% | 0.33x | 1.35x | NT$-35.69 Million |
Industry Comparison
This section compares SciVision Biotech Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,278,518,222
- Average return on equity (ROE) among peers: 10.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SciVision Biotech Inc (1786) | NT$1.86 Billion | -62.47% | 0.48x | $100.20 Million |
| St.Shine Optical Co Ltd (1565) | $6.14 Billion | 8.90% | 0.26x | $153.28 Million |
| Maxigen Biotech Inc (1783) | $1.54 Billion | 17.25% | 0.23x | $102.58 Million |
| Bioteque (4107) | $2.14 Billion | 14.22% | 0.23x | $243.43 Million |
| Chi Sheng Chemical (4111) | $1.22 Billion | 5.63% | 0.45x | $54.29 Million |
| BenQ Medical Technology (4116) | $2.18 Billion | 5.26% | 1.16x | $55.53 Million |
| Pacific Hospital Supply Co Ltd (4126) | $2.83 Billion | 14.85% | 0.33x | $177.95 Million |
| Bionime Corp (4737) | $1.99 Billion | 0.31% | 1.66x | $146.83 Million |
| Vizionfocus Inc. (4771) | $2.02 Billion | 15.48% | 0.59x | $393.98 Million |
| Formosa Optical Technology Co Ltd (5312) | $447.89 Million | 9.57% | 0.73x | $170.87 Million |
About SciVision Biotech Inc
SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. It also involved in international trade; wholesale of medical equipment and cosmetics; and provides management advisory services. SciVision Biotech Inc. was fo… Read more